Will You Still Study Me When I’m 64?

When older patients seek out health care, they are unwittingly enrolling in an experiment: Will medical procedures that have been proved effective mainly on the young also help the elderly?

That’s the first sentence in the editorial that my colleague Dr. Donna Zulman and I have in the New York Times today. We discuss the exclusion of older patients from many medical research studies and how it both compromises quality of care and is socially unjust. It’s a specific example of the more general problem I have discussed before: The people who are enrolled in the research studies that guide the provision of health care are markedly different from real-world patients on many dimensions.

When I was a member of an National Institutes of Health (NIH) grant review section, I saw many proposals that restricted study enrollment to people under the age of 55 or 60 or 62 or 65. I would always ask “If a patient otherwise enrollable was one day over your upper age limit, how would you justify excluding them to their face?”. The dominant response by grant applicants was interesting:

“I don’t know”.

What I began to see is that many exclusion criteria in research studies are simply cut and pastes from prior grant proposals and no one really knows where they came from or wants to defend them when asked. Authors of grant proposals debated many of the suggestions I made as a reviewer (which is appropriate) but never in my four years on the committee did someone argue that it was important that no one over the age of 55 or 60 or 62 or 65 be allowed to enroll. Exclusion of older people is simply a bad habit/tradition, with no strong defenders or even much thinking behind it, which is why I think NIH would encounter little resistance if it adopted the elderly patient-friendly reforms Donna and I propose.

The unnecessary exclusion of many patients from medical research is a serious ethical and clinical challenge to the future of health care. With welcome support from The Greenwall Foundation, I personally intend to make this problem a major focus of my work in the coming years.

[Cross-posted at The Reality-Based Community]

Keith Humphreys

Keith Humphreys is a professor of psychiatry at Stanford University. He served as a senior policy advisor at the White House Office of National Drug Control Policy from 2009 to 2010.